Group 1 - Aquestive Therapeutics (AQST) shares increased by 16% to $6.09, with a notable trading volume, following a 93% gain over the past four weeks [1] - The stock price surge is linked to the successful achievement of primary and secondary endpoints in a phase III clinical study for Anaphylm (epinephrine) Sublingual Film, aimed at treating severe allergic reactions [1] - The company plans to file a new drug application for Anaphylm by the end of 2024, which is expected to further influence stock performance [1] Group 2 - The upcoming quarterly report for Aquestive Therapeutics is projected to show a loss of $0.09 per share, a year-over-year decline of 181.8%, with revenues expected to reach $12.47 million, reflecting a 12% increase from the previous year [2] - The consensus EPS estimate for the quarter has been revised 13.3% higher in the last 30 days, indicating a potential for price appreciation [2] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook compared to other stocks in the same industry [3] Group 3 - Collegium Pharmaceutical (COLL), a peer in the Zacks Medical - Drugs industry, saw a 2.8% increase in its stock price, with a 12% return over the past month [3] - Collegium's consensus EPS estimate has risen by 11.9% over the past month, indicating positive momentum in earnings expectations [3] - Collegium Pharmaceutical holds a Zacks Rank of 1 (Strong Buy), contrasting with Aquestive's current ranking [3]

Anaphylm meets all predefined primary and secondary pharmacokinetic endpointsAnaphylm time to maximum concentration (Tmax) is consistently faster than autoinjectorsAnaphylm exposure levels (AUC) are comparable to autoinjectors for 30 minutes after dosing Anaphylm is well-tolerated with no serious adverse events Company receives positive Type C meeting feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical development of Anaphylm Company reaffirms goal of filing NDA before the end o ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Officer Carl Kraus - Chief Medical Officer Conference Call Participants François Brisebois - Oppenheimer Jason Butler - Citizens JMP Securities Andreas Argyrides - Wedbush Thomas Flaten - Lake Street Capital Markets Ram Selvaraju - H.C. Wainwright James Molloy - Alliance G ...

Financial Performance - The company exceeded its revenue and Non-GAAP Adjusted EBITDA guidance[5] - A $45 million debt refinancing resulted in approximately $28 million cash savings through June 2025[5] - The company finished the year with approximately $24 million in cash[5, 9] Anaphylm (epinephrine) sublingual film - The company is on track for submission of a New Drug Application (NDA) before year end 2024[6] - Positive top-line data was reported from pilot studies in 2023[6] - A pivotal trial commenced in December 2023, with top-line data expected in March 2024[6, 9] Libervant (diazepam) buccal film - An NDA was submitted for Libervant for patients between the ages of two and five years old[7] - The PDUFA action date is April 28, 2024[7] 2024 Outlook - The company expects total revenues of approximately $48 to $51 million[26] - The company anticipates a Non-GAAP adjusted EBITDA loss of approximately $22 to $26 million[26]

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.11 per share when it actually produced a loss of $0.03, delivering a surprise of 72.73%.Over the last four quar ...

Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual Film in March 2024Reaffirms anticipated FDA decision on Libervant™ (diazepam) Buccal Film application in April 2024Provides full year 2024 financial guidanceHosts investment community conference call on March 6, 2024 WARREN, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ C ...

Core Viewpoint - The average brokerage recommendation (ABR) for Aquestive Therapeutics (AQST) is 1.00, indicating a Strong Buy based on recommendations from four brokerage firms, all of which are Strong Buy [1][2]. Group 1: Brokerage Recommendations - The ABR of 1.00 is derived from four Strong Buy recommendations, representing 100% of the total recommendations [1]. - Despite the positive ABR, studies indicate that brokerage recommendations may not effectively guide investors in selecting stocks with the highest price increase potential [2][5]. - Brokerage firms often exhibit a strong positive bias in their ratings due to vested interests, leading to a disproportionate number of Strong Buy recommendations compared to Strong Sell [2][3]. Group 2: Zacks Rank vs. ABR - The Zacks Rank is a quantitative model based on earnings estimate revisions, providing a more reliable indicator of near-term stock performance compared to the ABR [4][5]. - The Zacks Rank is displayed in whole numbers (1 to 5) and maintains a balance among the ranks, while the ABR is calculated based on brokerage recommendations and can include decimals [4][5]. - The Zacks Rank is updated more frequently, reflecting timely changes in earnings estimates, unlike the ABR which may not be current [6]. Group 3: Current Earnings Estimates for AQST - The Zacks Consensus Estimate for Aquestive Therapeutics remains unchanged at -$0.07 for the current year, suggesting steady analyst views on the company's earnings prospects [7]. - The unchanged consensus estimate has resulted in a Zacks Rank of 3 (Hold) for Aquestive Therapeutics, indicating a cautious approach despite the Buy-equivalent ABR [7].

In the latest market close, Aquestive Therapeutics (AQST) reached $3.67, with a +0.55% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.52% for the day. Meanwhile, the Dow experienced a rise of 0.12%, and the technology-dominated Nasdaq saw an increase of 0.9%.The specialty pharmaceutical company's stock has climbed by 52.72% in the past month, exceeding the Medical sector's gain of 5.15% and the S&P 500's gain of 3.85%.The investment community will be clos ...

Aquestive Therapeutics (AQST) is expected to report fourth-quarter and full-year 2023 results later this month or early next month. In the last reported quarter, the company beat earnings expectations by 72.73%.Factors to ConsiderAquestive earns royalty revenues from its five out-licensed marketed products that it supplies under license deals with partners. Aquestive is the exclusive manufacturer of these licensed products. Its revenues from these products are expected to have increased in the fourth quarte ...